Basilar Artery Occlusion Chinese Endovascular Trial in the Extended Time Window
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorCapital Medical University
About this trial
A prospective, multi-center, randomized, controlled, open-label, blinded-endpoint trial to evaluate the safety and efficacy of endovascular mechanical thrombectomy for acute basilar artery occlusion in the extended time window
Eligibility criteria
Qualifiers
Posterior circulation acute ischemic stroke within 24-72 hours from symptom onset/last seen well (except for isolated vertigo), where patient is ineligible for IV thrombolytic treatment or the treatment is contraindicated (e.g., patient presents beyond recommended time from symptom onset), or where patient has received IV thrombolytic therapy without recanalization.
Occlusion (TIMI 0-1) of the basilar artery or intracranial segments of both vertebral arteries (V4) as evidenced by CTA/MRA/DSA.
Age ≥18 and ≤ 80.
Baseline NIHSS score obtained prior to randomization must be equal or higher than 6 points.
Disqualifiers
Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR > 3.0.
Baseline platelet count < 50000/µL.
Baseline blood glucose of < 50mg/dL or >400mg/dl.
Severe, sustained hypertension (SBP > 220 mm Hg or DBP > 110 mm Hg) NOTE: If the blood pressure can be successfully reduced and maintained below these levels using commonly used medications in China for these purposes (including iv antihypertensive drips), the patient can be enrolled.
Trial design
Treatments tested in this trial
- Mechanical thrombectomy
Treatment groups
309 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov